Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C
Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
This study was conducted to determine the safety, tolerance, pharmacokinetics and antiviral
activity of val-mCyd at doses ranging from 50 mg to 800 mg per day.